Key Events This Week
16 Feb: Quality grade upgraded to Strong Buy amid robust financial metrics
17 Feb: Stock hits upper circuit at Rs.128.70 on strong buying pressure
19 Feb: Lower circuit hit at Rs.124.55 amid heavy selling pressure
20 Feb: Week closes at Rs.122.70, down 4.59%

Quest Laboratories Ltd Hits Lower Circuit Amid Heavy Selling Pressure
2026-02-19 15:00:09Quest Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a sharp decline on 19 Feb 2026, hitting its lower circuit limit amid intense selling pressure. The stock closed at ₹124.55, down 5.0% on the day, reflecting panic selling and unfilled supply that overwhelmed demand despite the company’s strong fundamentals and recent upgrade to a Strong Buy rating.
Read full news article
Quest Laboratories Ltd is Rated Strong Buy
2026-02-19 10:10:50Quest Laboratories Ltd is rated Strong Buy by MarketsMOJO, with this rating last updated on 16 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 February 2026, providing investors with the most up-to-date perspective on the company’s performance and outlook.
Read full news article
Quest Laboratories Ltd Hits Upper Circuit Amid Robust Buying Pressure
2026-02-17 14:00:09Quest Laboratories Ltd surged to its upper circuit limit on 17 Feb 2026, propelled by strong buying interest and heightened investor participation. The stock closed at ₹128.70, marking a maximum daily gain of 4.98%, significantly outperforming its sector and the broader market indices.
Read full news article
Quest Laboratories Ltd Upgrades Quality Grade Amid Strong Financial Metrics
2026-02-17 08:01:27Quest Laboratories Ltd has recently seen its quality grade upgraded from average to good, reflecting significant improvements in its core business fundamentals. This upgrade, accompanied by a strong Mojo Score of 81.0 and a revised Mojo Grade of Strong Buy, signals enhanced operational efficiency, robust profitability, and prudent financial management within the pharmaceuticals and biotechnology sector.
Read full news article









